Atomo Diagnostics Ltd (AU:AT1) — Market Cap & Net Worth
Market Cap & Net Worth: Atomo Diagnostics Ltd (AT1)
Atomo Diagnostics Ltd (AU:AT1) has a market capitalization of $10.85 Million (AU$15.34 Million) as of September 24, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26953 globally and #1264 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Atomo Diagnostics Ltd's stock price AU$0.02 by its total outstanding shares 902432853 (902.43 Million). Also see AT1 total assets for a full breakdown of the balance sheet.
Atomo Diagnostics Ltd Market Cap History: 2020 to 2026
Atomo Diagnostics Ltd's market capitalization history from 2020 to 2026. Data shows change from $194.75 Million to $10.85 Million (-38.53% CAGR). Also see Atomo Diagnostics Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Atomo Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Atomo Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Atomo Diagnostics Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6.06x
Atomo Diagnostics Ltd's market cap is 6.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $194.75 Million | $5.37 Million | -$9.22 Million | 36.28x | N/A |
| 2021 | $191.56 Million | $6.72 Million | -$6.02 Million | 28.52x | N/A |
| 2022 | $34.48 Million | $12.34 Million | -$5.71 Million | 2.80x | N/A |
| 2023 | $14.05 Million | $2.54 Million | -$9.96 Million | 5.52x | N/A |
| 2024 | $12.13 Million | $4.09 Million | -$6.85 Million | 2.97x | N/A |
| 2025 | $22.99 Million | $3.79 Million | -$4.97 Million | 6.06x | N/A |
Competitor Companies of AT1 by Market Capitalization
Companies near Atomo Diagnostics Ltd in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Atomo Diagnostics Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Atomo Diagnostics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #122 globally with a market cap of $180.30 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #237 globally with a market cap of $105.52 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #122 | Abbott Laboratories | NYSE:ABT | $180.30 Billion | $103.69 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $90.77 |
| #237 | Stryker Corporation | NYSE:SYK | $105.52 Billion | $275.09 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Atomo Diagnostics Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Atomo Diagnostics Ltd's market cap moved from $194.75 Million to $ 10.85 Million, with a yearly change of -38.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$10.85 Million | -52.78% |
| 2025 | AU$22.99 Million | +89.47% |
| 2024 | AU$12.13 Million | -13.64% |
| 2023 | AU$14.05 Million | -59.26% |
| 2022 | AU$34.48 Million | -82.00% |
| 2021 | AU$191.56 Million | -1.64% |
| 2020 | AU$194.75 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Atomo Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.85 Million USD |
| MoneyControl | $10.85 Million USD |
| MarketWatch | $10.85 Million USD |
| marketcap.company | $10.85 Million USD |
| Reuters | $10.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.